Form 4: Christine Brennan Acquires Stock Options in Boundless Bio, Inc.
SEC Form 4 Filing
Christine Brennan, a Director of Boundless Bio, Inc., acquired stock options for 26,438 shares on March 27, 2024.
Summary
- On March 27, 2024, Christine Brennan, a Director of Boundless Bio, Inc. (ticker: BOLD), acquired stock options for 26,438 shares.
- The stock options have an exercise price of $0.
- The options vest in 36 substantially equal monthly installments beginning on April 27, 2024.
- The options expire on March 26, 2034.
- Following the transaction, Ms. Brennan directly owns 26,438 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of an insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the holdings and transactions of company directors. It is standard practice for directors to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of transaction: Christine Brennan acquired stock options. |
| 04/27/2024 | Vesting start date: Stock options vest in 36 substantially equal monthly installments beginning on this date. |
| 03/26/2034 | Expiration date: Stock options expire on this date. |
| 03/29/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.